Home
TVGN
TVGN News

Latest Tevogen Bio Holdings Inc. Common Stock (TVGN) News on March 29, 2025

Tevogen Bio CEO Named to NJBIZ 2025 Health Care Power List as Company Advances Commercialization; Reaffirms Timeframe on Previously Announced Forecast

GlobeNewswire

3 days ago

Tevogen Bio CEO Named to NJBIZ 2025 Health Care Power List as Company Advances Commercialization; Reaffirms Timeframe on Previously Announced Forecast

Tevogen Bio Appoints David E. Banko as Global Head of Government Affairs and Patient Access, Advances Commercialization Plan

GlobeNewswire

4 days ago

Tevogen Bio Appoints David E. Banko as Global Head of Government Affairs and Patient Access, Advances Commercialization Plan

Tevogen Bio Announces Unique T Cell Vaccine Under Development and Files Patent with the USPTO

GlobeNewswire

19 days ago

Tevogen Bio Announces Unique T Cell Vaccine Under Development and Files Patent with the USPTO

Tevogen Bio’s CIO & Head of Tevogen.AI, Mittul Mehta, Featured Speaker at Proskauer’s AI Discussion Panel

GlobeNewswire

22 days ago

Tevogen Bio’s CIO & Head of Tevogen.AI, Mittul Mehta, Featured Speaker at Proskauer’s AI Discussion Panel

Tevogen Bio to Receive $8 Million of Non-Dilutive Grant Funding, Reiterates Efficient Operations

GlobeNewswire

a month ago

Tevogen Bio to Receive $8 Million of Non-Dilutive Grant Funding, Reiterates Efficient Operations

Tevogen Bio Founder and CEO Dr. Ryan Saadi Named to 2025 NJBIZ Power 100, Celebrating Innovation and Leadership in Accessible T Cell Therapy

GlobeNewswire

a month ago

Tevogen Bio Founder and CEO Dr. Ryan Saadi Named to 2025 NJBIZ Power 100, Celebrating Innovation and Leadership in Accessible T Cell Therapy

Tevogen Bio’s First Trading Year Efficiency: 600% Higher Market Cap Per Team Member, 79% Insider-Owned

GlobeNewswire

a month ago

Tevogen Bio’s First Trading Year Efficiency: 600% Higher Market Cap Per Team Member, 79% Insider-Owned

Tevogen Bio Shares 2024 Financing Activity on One Year Anniversary of Becoming a Publicly Listed Company; Highlights Operational Efficiency

GlobeNewswire

a month ago

Tevogen Bio Shares 2024 Financing Activity on One Year Anniversary of Becoming a Publicly Listed Company; Highlights Operational Efficiency

Tevogen Bio CEO Addresses Short Selling and Its Potential Impact on the Nation’s Health and Prosperity

GlobeNewswire

a month ago

Tevogen Bio CEO Addresses Short Selling and Its Potential Impact on the Nation’s Health and Prosperity

Tevogen Bio CEO Congratulates RFK Jr. on His Confirmation as Secretary of the HHS; Echoes Commitment to Innovation and Affordability for Americans

GlobeNewswire

a month ago

Tevogen Bio CEO Congratulates RFK Jr. on His Confirmation as Secretary of the HHS; Echoes Commitment to Innovation and Affordability for Americans

Tevogen Bio's Business Model Addresses Biopharma Industry Challenges with Cost-Efficient Innovation

GlobeNewswire

2 months ago

Tevogen Bio's Business Model Addresses Biopharma Industry Challenges with Cost-Efficient Innovation

Tevogen Bio Meets BARDA TechWatch Team, Highlighting ExacTcell™ Technology’s Potential as a Scalable Medical Countermeasure

GlobeNewswire

2 months ago

Tevogen Bio Meets BARDA TechWatch Team, Highlighting ExacTcell™ Technology’s Potential as a Scalable Medical Countermeasure

Tevogen Bio Enters Agreement to Receive Up To $10 Million of Non-Dilutive Grant Funding

GlobeNewswire

2 months ago

Tevogen Bio Enters Agreement to Receive Up To $10 Million of Non-Dilutive Grant Funding

Tevogen Bio CEO Congratulates Lynne Patton on Being Appointed Deputy Assistant to the President and Director of Minority Outreach

GlobeNewswire

2 months ago

Tevogen Bio CEO Congratulates Lynne Patton on Being Appointed Deputy Assistant to the President and Director of Minority Outreach

Tevogen Bio Broadens Relationship with Microsoft to Deepen Artificial Intelligence Collaboration and Develop PredicTcell Technology on Azure

GlobeNewswire

2 months ago

Tevogen Bio Broadens Relationship with Microsoft to Deepen Artificial Intelligence Collaboration and Develop PredicTcell Technology on Azure

Tevogen Bio Highlights the Future of AI-Driven Drug Development in Fireside Chat with Microsoft During the J.P. Morgan Healthcare Conference

GlobeNewswire

2 months ago

Tevogen Bio Highlights the Future of AI-Driven Drug Development in Fireside Chat with Microsoft During the J.P. Morgan Healthcare Conference

Tevogen Bio to Host Panel Discussions “AI In Biopharma: Next Frontier of Medical Innovation” and “Pioneering the Economics of Health: Balancing Access and Outcomes” During J.P. Morgan Healthcare Conference

GlobeNewswire

3 months ago

Tevogen Bio to Host Panel Discussions “AI In Biopharma: Next Frontier of Medical Innovation” and “Pioneering the Economics of Health: Balancing Access and Outcomes” During J.P. Morgan Healthcare Conference

Tevogen Bio to Host Panel "AI In Biopharma: Next Frontier of Medical Innovation" During the 43rd Annual J.P. Morgan Healthcare Conference

GlobeNewswire

3 months ago

Tevogen Bio to Host Panel "AI In Biopharma: Next Frontier of Medical Innovation" During the 43rd Annual J.P. Morgan Healthcare Conference

Tevogen Bio Strengthens Robust IP Portfolio With Filing of Predictive AI Patent, With the Goal to Establish a Blueprint to Unlock the Full Potential of T Cell Therapies and Accelerate AI Integration to Advance Its Bold Growth Agenda

GlobeNewswire

3 months ago

Tevogen Bio Strengthens Robust IP Portfolio With Filing of Predictive AI Patent, With the Goal to Establish a Blueprint to Unlock the Full Potential of T Cell Therapies and Accelerate AI Integration to Advance Its Bold Growth Agenda

Tevogen Bio to Host Panel “Pioneering the Economics of Health: Balancing Access and Outcomes” During the 43rd Annual J.P. Morgan Healthcare Conference

GlobeNewswire

3 months ago

Tevogen Bio to Host Panel “Pioneering the Economics of Health: Balancing Access and Outcomes” During the 43rd Annual J.P. Morgan Healthcare Conference

Tevogen Bio to Attend the 43rd Annual J.P. Morgan Healthcare Conference

GlobeNewswire

4 months ago

Tevogen Bio to Attend the 43rd Annual J.P. Morgan Healthcare Conference

Dr. Ryan Saadi Commends Individuals Who Dedicate Time to Public Service, and Congratulates Mayor Victor Sordillo on His Induction Into the NJ League of Municipalities Hall of Fame

GlobeNewswire

4 months ago

Dr. Ryan Saadi Commends Individuals Who Dedicate Time to Public Service, and Congratulates Mayor Victor Sordillo on His Induction Into the NJ League of Municipalities Hall of Fame

Tevogen Bio Prepares Organizational Readiness to Support Company’s Growth Strategy

GlobeNewswire

4 months ago

Tevogen Bio Prepares Organizational Readiness to Support Company’s Growth Strategy

Tevogen Bio CEO Reflects on Public Support, Reaffirms Preserving Shareholder Value Remains His Priority, and Reinforces Options Including a Potential Share Buyback to Support Company Value

GlobeNewswire

4 months ago

Tevogen Bio CEO Reflects on Public Support, Reaffirms Preserving Shareholder Value Remains His Priority, and Reinforces Options Including a Potential Share Buyback to Support Company Value

Tevogen Bio Reports Third Quarter 2024 Financial Results; Highlights Significantly Improved Financial Position, Unreported Asset Value on Balance Sheets, Efficient Business Model

GlobeNewswire

4 months ago

Tevogen Bio Reports Third Quarter 2024 Financial Results; Highlights Significantly Improved Financial Position, Unreported Asset Value on Balance Sheets, Efficient Business Model

UPDATE - Tevogen Founder Reflects on Importance of Preserving Shareholder Value While Navigating Growth as it Prepares to File Quarterly Financials

GlobeNewswire

4 months ago

UPDATE - Tevogen Founder Reflects on Importance of Preserving Shareholder Value While Navigating Growth as it Prepares to File Quarterly Financials

Tevogen Founder Reflects on Importance of Preserving Shareholder Value While Navigating Growth as it Prepares to File Quarterly Financials

GlobeNewswire

4 months ago

Tevogen Founder Reflects on Importance of Preserving Shareholder Value While Navigating Growth as it Prepares to File Quarterly Financials

Tevogen Bio Nears Finalization of Agreement to Enhance R&D and Manufacturing Capabilities; $36 Million Line of Credit Available for Continued Operations

GlobeNewswire

5 months ago

Tevogen Bio Nears Finalization of Agreement to Enhance R&D and Manufacturing Capabilities; $36 Million Line of Credit Available for Continued Operations

Tevogen Bio CEO Dr. Ryan Saadi Expresses Gratitude for Prestigious ROI-NJ Recognition, Highlighting Company’s Novel Business Model as Key to Sustainable Success through Patient Affordability

GlobeNewswire

5 months ago

Tevogen Bio CEO Dr. Ryan Saadi Expresses Gratitude for Prestigious ROI-NJ Recognition, Highlighting Company’s Novel Business Model as Key to Sustainable Success through Patient Affordability

Tevogen Bio Leverages Microsoft Partnership to Deliver Machine Learning Based Target Identification to Address Human Papilloma Virus (HPV), Advancing TVGN 920

GlobeNewswire

5 months ago

Tevogen Bio Leverages Microsoft Partnership to Deliver Machine Learning Based Target Identification to Address Human Papilloma Virus (HPV), Advancing TVGN 920

Tevogen Bio Announces Appointment of Anthony Tarantino as Patient Advocate to Enhance Community Engagement and Patient Support

GlobeNewswire

5 months ago

Tevogen Bio Announces Appointment of Anthony Tarantino as Patient Advocate to Enhance Community Engagement and Patient Support

Tevogen Bio Expands on Microsoft Partnership to Integrate Machine Learning and AI into Preclinical Processes, Accelerating Drug Development and Reducing Costs

GlobeNewswire

5 months ago

Tevogen Bio Expands on Microsoft Partnership to Integrate Machine Learning and AI into Preclinical Processes, Accelerating Drug Development and Reducing Costs

Tevogen Bio Reports Nasdaq Listing Compliance as CEO Reaffirms His Commitment in Bridging the Information Gap About the Company

GlobeNewswire

5 months ago

Tevogen Bio Reports Nasdaq Listing Compliance as CEO Reaffirms His Commitment in Bridging the Information Gap About the Company

Tevogen Bio Signs Letter of Intent With CD8 Technology to Build Up to a $50 Million R&D and Manufacturing Facility; No Impact on Shareholder Equity

GlobeNewswire

5 months ago

Tevogen Bio Signs Letter of Intent With CD8 Technology to Build Up to a $50 Million R&D and Manufacturing Facility; No Impact on Shareholder Equity

Tevogen Bio Provides Additional Guidance on Introduction of T Cell Therapy for Oncology and Specialty Care Therapeutic Areas

GlobeNewswire

5 months ago

Tevogen Bio Provides Additional Guidance on Introduction of T Cell Therapy for Oncology and Specialty Care Therapeutic Areas

Tevogen Bio’s Effort in Artificial Intelligence, Tevogen AI, Joins Microsoft for Startups, Begins Accelerating drug Development

GlobeNewswire

5 months ago

Tevogen Bio’s Effort in Artificial Intelligence, Tevogen AI, Joins Microsoft for Startups, Begins Accelerating drug Development

Tevogen Bio To Provide Timelines Associated with Recently Announced Revenue Forecast and Updates on Operational Readiness This Week

GlobeNewswire

5 months ago

Tevogen Bio To Provide Timelines Associated with Recently Announced Revenue Forecast and Updates on Operational Readiness This Week

Tevogen Bio Specialty Care Reports Top-Line Revenue Forecast of Nearly $1 Billion in Launch Year and Cumulative 5-Year Estimate Between $18 Billion and $22 Billion

GlobeNewswire

5 months ago

Tevogen Bio Specialty Care Reports Top-Line Revenue Forecast of Nearly $1 Billion in Launch Year and Cumulative 5-Year Estimate Between $18 Billion and $22 Billion

Tevogen Bio Provides Clarity on CSO Share Sales to Satisfy Tax Obligations, Expects Additional Forecast and Progress Updates in the Coming Days

GlobeNewswire

5 months ago

Tevogen Bio Provides Clarity on CSO Share Sales to Satisfy Tax Obligations, Expects Additional Forecast and Progress Updates in the Coming Days

Tevogen CEO Expresses Gratitude for Unprecedented Public Support of Company’s Business Model of Commercial Success Through Patient Accessibility and Reaffirms His Commitment to Share Additional Details in the Coming Days

GlobeNewswire

5 months ago

Tevogen CEO Expresses Gratitude for Unprecedented Public Support of Company’s Business Model of Commercial Success Through Patient Accessibility and Reaffirms His Commitment to Share Additional Details in the Coming Days

Tevogen Bio Oncology Reports Top-Line Revenue Forecast of $1 Billion in Launch Year and Cumulative 5-Year Estimate Between $10 Billion and $14 Billion; Forecasts for Non-Oncology Therapeutic Areas to Follow

GlobeNewswire

5 months ago

Tevogen Bio Oncology Reports Top-Line Revenue Forecast of $1 Billion in Launch Year and Cumulative 5-Year Estimate Between $10 Billion and $14 Billion; Forecasts for Non-Oncology Therapeutic Areas to Follow

Tevogen Investors Congratulate on Prestigious Recognition of Pioneering Biopharma Business Model, Breakthrough Innovations, Building Assets Estimated to Exceed $10 Billion

GlobeNewswire

5 months ago

Tevogen Investors Congratulate on Prestigious Recognition of Pioneering Biopharma Business Model, Breakthrough Innovations, Building Assets Estimated to Exceed $10 Billion

Tevogen Bio Thanks Warren Township for Proclamation Honoring CEO Dr. Ryan Saadi, Nobel Peace Prize Nomination, and the Company's Mission to Address Health Inequality

GlobeNewswire

5 months ago

Tevogen Bio Thanks Warren Township for Proclamation Honoring CEO Dr. Ryan Saadi, Nobel Peace Prize Nomination, and the Company's Mission to Address Health Inequality

Tevogen Bio Takes Lead in Developing Cell Therapies Designed to Eradicate Post Procedure Human Papilloma Virus in Women with Precancerous Cervical Lesions

GlobeNewswire

5 months ago

Tevogen Bio Takes Lead in Developing Cell Therapies Designed to Eradicate Post Procedure Human Papilloma Virus in Women with Precancerous Cervical Lesions

Tevogen Bio Highlights the Publication of Promising Trial Data as the CEO Expresses Optimism About the Company’s Scientific Breakthrough in Mainstreaming Cell Therapy Through a New Class of Off-the-Shelf T-Cell Therapies, Manufactured and Stored for Immediate Use

GlobeNewswire

5 months ago

Tevogen Bio Highlights the Publication of Promising Trial Data as the CEO Expresses Optimism About the Company’s Scientific Breakthrough in Mainstreaming Cell Therapy Through a New Class of Off-the-Shelf T-Cell Therapies, Manufactured and Stored for Immediate Use

Tevogen CEO Reaffirms the Company’s Commitment to Closing the Information Gap on Its Multi-Billion-Dollar Assets, Following the Release of Revenue Projections

GlobeNewswire

5 months ago

Tevogen CEO Reaffirms the Company’s Commitment to Closing the Information Gap on Its Multi-Billion-Dollar Assets, Following the Release of Revenue Projections

Tevogen Bio Plans to Share $1B+ Revenue Potential of its Pipeline Portfolio Beginning Week of October 14, 2024

GlobeNewswire

6 months ago

Tevogen Bio Plans to Share $1B+ Revenue Potential of its Pipeline Portfolio Beginning Week of October 14, 2024

Tevogen Bio Extends Pipeline Prioritizing Oncology and Long COVID

GlobeNewswire

6 months ago

Tevogen Bio Extends Pipeline Prioritizing Oncology and Long COVID

Tevogen Bio Highlights Promising Trial Data as CEO Leads Patient Advocacy at Capitol Hill, Pledging to Leverage Multi-Billion Dollar Company Assets to Combat Long COVID and Spearhead a New Wave of Medical Innovation

GlobeNewswire

6 months ago

Tevogen Bio Highlights Promising Trial Data as CEO Leads Patient Advocacy at Capitol Hill, Pledging to Leverage Multi-Billion Dollar Company Assets to Combat Long COVID and Spearhead a New Wave of Medical Innovation

Tevogen Bio Leadership Meets Members of U.S. Congress to Advocate for Long COVID Patients and Highlights Achievements and Assets as a Blueprint for Biotech Innovation

GlobeNewswire

6 months ago

Tevogen Bio Leadership Meets Members of U.S. Congress to Advocate for Long COVID Patients and Highlights Achievements and Assets as a Blueprint for Biotech Innovation

Tevogen Bio Secures $6 Million Series C Preferred Stock Investment

GlobeNewswire

7 months ago

Tevogen Bio Secures $6 Million Series C Preferred Stock Investment

CORRECTION – Tevogen Bio Reports Second Quarter 2024 Financial Results, Eliminates Doubt About Company’s Ability to Continue as a Going Concern, Eliminates Series B Preferred Shares

GlobeNewswire

7 months ago

CORRECTION – Tevogen Bio Reports Second Quarter 2024 Financial Results, Eliminates Doubt About Company’s Ability to Continue as a Going Concern, Eliminates Series B Preferred Shares

Tevogen Bio Reports Second Quarter 2024 Financial Results, Eliminates Doubt About Company’s Ability to Continue as a Going Concern, Eliminates Series B Preferred Shares

GlobeNewswire

7 months ago

Tevogen Bio Reports Second Quarter 2024 Financial Results, Eliminates Doubt About Company’s Ability to Continue as a Going Concern, Eliminates Series B Preferred Shares

Tevogen Bio’s Innovation and Public Health Advisory Board Chairperson, Professor Sten Vermund, Appointed Dean of the University of South Florida Health College of Public Health

GlobeNewswire

7 months ago

Tevogen Bio’s Innovation and Public Health Advisory Board Chairperson, Professor Sten Vermund, Appointed Dean of the University of South Florida Health College of Public Health

Tevogen Bio’s Founding CEO, Ryan Saadi, Expresses Conviction in Company’s Growth Strategy and Reaffirms Newly Effective Form S-1 Does Not Relate to Previously Undisclosed New Issuance of Dilutive Securities

GlobeNewswire

8 months ago

Tevogen Bio’s Founding CEO, Ryan Saadi, Expresses Conviction in Company’s Growth Strategy and Reaffirms Newly Effective Form S-1 Does Not Relate to Previously Undisclosed New Issuance of Dilutive Securities

Tevogen Bio Issues Letter to Stockholders Highlighting Recent Achievements, Growth Plans, and Consideration of a Potential Share Buyback

GlobeNewswire

9 months ago

Tevogen Bio Issues Letter to Stockholders Highlighting Recent Achievements, Growth Plans, and Consideration of a Potential Share Buyback

Tevogen Bio’s R&D Leadership Discusses The Promise of Its Genetically Unmodified, Off-The-Shelf T Cell Technology For The Treatment of Infectious Diseases, Cancers, and Neurological Disorders With Nasdaq's Kristina Ayanian

GlobeNewswire

9 months ago

Tevogen Bio’s R&D Leadership Discusses The Promise of Its Genetically Unmodified, Off-The-Shelf T Cell Technology For The Treatment of Infectious Diseases, Cancers, and Neurological Disorders With Nasdaq's Kristina Ayanian

Ryan Saadi Congratulates Marc Benioff on Receiving the Yale Legend in Leadership Award and Commends Yale School of Management for Recognizing the Importance of Integrating Corporate Success with Social Responsibility

GlobeNewswire

9 months ago

Ryan Saadi Congratulates Marc Benioff on Receiving the Yale Legend in Leadership Award and Commends Yale School of Management for Recognizing the Importance of Integrating Corporate Success with Social Responsibility

Tevogen Bio Files Registration Statement for Previously Disclosed Securities; Does Not Relate to Any Previously Undisclosed New Issuances of Dilutive Securities

GlobeNewswire

9 months ago

Tevogen Bio Files Registration Statement for Previously Disclosed Securities; Does Not Relate to Any Previously Undisclosed New Issuances of Dilutive Securities

Tevogen Bio Announces Publication of Positive Phase I Clinical Trial Results for TVGN 489 in Blood Advances

GlobeNewswire

9 months ago

Tevogen Bio Announces Publication of Positive Phase I Clinical Trial Results for TVGN 489 in Blood Advances

Tevogen.AI Head Discusses Company’s Bold Strategy to Shape the Future of T Cell Therapies at Longwood Spring MIT Conference

GlobeNewswire

9 months ago

Tevogen.AI Head Discusses Company’s Bold Strategy to Shape the Future of T Cell Therapies at Longwood Spring MIT Conference

Tevogen Bio Set to Join Russell 3000® Index

GlobeNewswire

10 months ago

Tevogen Bio Set to Join Russell 3000® Index

Tevogen Bio Enters Into Agreement for Up to $50 Million in Financing to Advance R&D and Clinical Development Efforts

GlobeNewswire

10 months ago

Tevogen Bio Enters Into Agreement for Up to $50 Million in Financing to Advance R&D and Clinical Development Efforts

NexTech Solutions Has Agreed to Acquire Rome Research Corporation to Expand Service Offerings and Enhance Mission Support Capabilities

PR Newswire

10 months ago

NexTech Solutions Has Agreed to Acquire Rome Research Corporation to Expand Service Offerings and Enhance Mission Support Capabilities

Enhancing the Power of PTZs: Canon Announces New PTZ Firmware Updates Lending Greater Control and Operability, Including an Auto-Tracking Lite Version on Compatible PTZ Models*

GlobeNewswire

10 months ago

Enhancing the Power of PTZs: Canon Announces New PTZ Firmware Updates Lending Greater Control and Operability, Including an Auto-Tracking Lite Version on Compatible PTZ Models*

Business Wire

10 months ago

Form 8.3 - International Distribution Services plc

Business Wire

10 months ago

Form 8.3 - Darktrace plc

US Supreme Court rejects Kroger challenge to Grubhub trademark win

Reuters

10 months ago

US Supreme Court rejects Kroger challenge to Grubhub trademark win

Dow Jones Falls As AMD Slides On Downgrade; Nvidia Stock Split Takes Effect

Investor's Business Daily

10 months ago

Dow Jones Falls As AMD Slides On Downgrade; Nvidia Stock Split Takes Effect

GoldATM Supports Growing Consumer Demand for Gold Purchase with New ATMs in North Carolina

Business Wire

10 months ago

GoldATM Supports Growing Consumer Demand for Gold Purchase with New ATMs in North Carolina

GlobeNewswire

10 months ago

Middlefield Canadian Income PCC: Net Asset Value(s)

CORRECTION – Tevogen Bio Expresses Gratitude to Patients, First Responders, Elected Officials, and Members of the United States Congress for Attending Its Inaugural Post-Public Listing Social Engagement Event

GlobeNewswire

10 months ago

CORRECTION – Tevogen Bio Expresses Gratitude to Patients, First Responders, Elected Officials, and Members of the United States Congress for Attending Its Inaugural Post-Public Listing Social Engagement Event

Tevogen Bio Expresses Gratitude to Patients, First Responders, Elected Officials, and Members of the United States Congress for Attending Its Inaugural Post-Listing Social Engagement Event

GlobeNewswire

10 months ago

Tevogen Bio Expresses Gratitude to Patients, First Responders, Elected Officials, and Members of the United States Congress for Attending Its Inaugural Post-Listing Social Engagement Event

Tevogen Bio Confirms Ongoing Efficacy of TVGN 489, Its Investigational Allogeneic Off-the-Shelf Immunotherapy, Against Dominant FLiRT Strains of SARS-CoV-2

GlobeNewswire

10 months ago

Tevogen Bio Confirms Ongoing Efficacy of TVGN 489, Its Investigational Allogeneic Off-the-Shelf Immunotherapy, Against Dominant FLiRT Strains of SARS-CoV-2

Tevogen Bio Reports First Quarter 2024 Financial Results

GlobeNewswire

10 months ago

Tevogen Bio Reports First Quarter 2024 Financial Results

Tevogen Bio Appoints Former Police Chief & FBI National Academy Graduate, William Keane, as Vice President of Strategic Initiatives

GlobeNewswire

10 months ago

Tevogen Bio Appoints Former Police Chief & FBI National Academy Graduate, William Keane, as Vice President of Strategic Initiatives

Tevogen Bio Announces Up to $50 Million in Financing to Further Advance Operational Objectives

GlobeNewswire

a year ago

Tevogen Bio Announces Up to $50 Million in Financing to Further Advance Operational Objectives

Tevogen Bio Announces Full Year 2023 Financial Results and Upcoming Operational Objectives

GlobeNewswire

a year ago

Tevogen Bio Announces Full Year 2023 Financial Results and Upcoming Operational Objectives

Tevogen Bio CEO Highlights Expected Reporting of a $94.9 Million Liability Elimination, AI Initiative, and Leadership Appointments

GlobeNewswire

a year ago

Tevogen Bio CEO Highlights Expected Reporting of a $94.9 Million Liability Elimination, AI Initiative, and Leadership Appointments

Tevogen Bio’s Chief Scientific Officer Speaks on the Harnessing of Cytotoxic T Lymphocytes (CTLs) to Target Cancers

GlobeNewswire

a year ago

Tevogen Bio’s Chief Scientific Officer Speaks on the Harnessing of Cytotoxic T Lymphocytes (CTLs) to Target Cancers

Tevogen Bio Appoints Tapan V Shah as Head of Investor Relations and Corporate Development

GlobeNewswire

a year ago

Tevogen Bio Appoints Tapan V Shah as Head of Investor Relations and Corporate Development

Tevogen Bio Reports Series A-1 Preferred Stock Investment at $10 Conversion Price

GlobeNewswire

a year ago

Tevogen Bio Reports Series A-1 Preferred Stock Investment at $10 Conversion Price

Tevogen Bio Reports Its Investigational SARS-CoV-2 Specific T Cell Therapy, TVGN-489, Retains Activity Against the Dominant JN.1 Variant

Business Wire

a year ago

Tevogen Bio Reports Its Investigational SARS-CoV-2 Specific T Cell Therapy, TVGN-489, Retains Activity Against the Dominant JN.1 Variant

Tevogen Bio Holdings Congratulates its Board Member and Esteemed Global Safety Management Expert, Victor Sordillo, on His appointment as Managing Director of Risk Advisory Services at Verita

Business Wire

a year ago

Tevogen Bio Holdings Congratulates its Board Member and Esteemed Global Safety Management Expert, Victor Sordillo, on His appointment as Managing Director of Risk Advisory Services at Verita

With a 86% stake, Tevogen Bio Holdings Inc. (NASDAQ:TVGN) insiders have a lot riding on the company

Simply Wall St.

a year ago

With a 86% stake, Tevogen Bio Holdings Inc. (NASDAQ:TVGN) insiders have a lot riding on the company

Mittul Mehta, Head of Tevogen's Artificial Intelligence Initiative Tevogen.ai, Emphasizes Importance of Proactive Talent Development for Biopharmaceutical Sector to Allow Rapid Adoption of AI

Business Wire

a year ago

Mittul Mehta, Head of Tevogen's Artificial Intelligence Initiative Tevogen.ai, Emphasizes Importance of Proactive Talent Development for Biopharmaceutical Sector to Allow Rapid Adoption of AI

Cell Therapy Company Tevogen Bio Holdings Inc. Prepares to Launch Crucial Genetic Predisposition Study in Preparation to Investigate the Potential of TVGN 489 to Address Critical Unmet Need for Long COVID Treatment

Business Wire

a year ago

Cell Therapy Company Tevogen Bio Holdings Inc. Prepares to Launch Crucial Genetic Predisposition Study in Preparation to Investigate the Potential of TVGN 489 to Address Critical Unmet Need for Long COVID Treatment

Cell Therapy Company Tevogen Bio Holdings Inc. (Nasdaq: TVGN) Rings Opening Bell at Nasdaq Exchange on February 15th, 2024, Begins Public Trading on the Open Market

Business Wire

a year ago

Cell Therapy Company Tevogen Bio Holdings Inc. (Nasdaq: TVGN) Rings Opening Bell at Nasdaq Exchange on February 15th, 2024, Begins Public Trading on the Open Market

Tevogen Bio Announces $8 Million Equity Investment

Business Wire

a year ago

Tevogen Bio Announces $8 Million Equity Investment

Share on Social Networks: